LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -11.83 Thousand USD | 21.12% |
| 2022 | -15 Thousand USD | -7.34% |
| 2021 | -13.97 Thousand USD | 51.86% |
| 2020 | -29.03 Thousand USD | -40.55% |
| 2019 | -20.65 Thousand USD | -108.26% |
| 2018 | 250 Thousand USD | 150.0% |
| 2017 | 100 Thousand USD | -50.0% |
| 2016 | 200 Thousand USD | 100.0% |
| 2015 | 100 Thousand USD | 0.0% |
| 2014 | 100 Thousand USD | -66.67% |
| 2013 | 300 Thousand USD | 200.0% |
| 2012 | 100 Thousand USD | -60.0% |
| 2011 | 250 Thousand USD | 150.0% |
| 2010 | 100 Thousand USD | -98.95% |
| 2009 | 9.5 Million USD | 51.61% |
| 2008 | 6.26 Million USD | -15.99% |
| 2007 | 7.45 Million USD | 261.09% |
| 2006 | 2.06 Million USD | 1020.47% |
| 2005 | 184.36 Thousand USD | -56.94% |
| 2004 | 428.16 Thousand USD | 355.49% |
| 2003 | 94 Thousand USD | -92.94% |
| 2002 | 1.33 Million USD | -69.26% |
| 2001 | 4.32 Million USD | 28.16% |
| 2000 | 3.37 Million USD | 457.39% |
| 1999 | 606 Thousand USD | -62.13% |
| 1998 | 1.6 Million USD | -79.75% |
| 1997 | 7.9 Million USD | 507.69% |
| 1996 | 1.3 Million USD | -23.53% |
| 1995 | 1.7 Million USD | -39.29% |
| 1994 | 2.8 Million USD | -39.13% |
| 1993 | 4.6 Million USD | 84.0% |
| 1992 | 2.5 Million USD | -47.92% |
| 1991 | 4.8 Million USD | 1100.0% |
| 1990 | 400 Thousand USD | 123.53% |
| 1989 | -1.7 Million USD | -288.89% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1401.00 USD | 31.99% |
| 2024 Q1 | -2060.00 USD | -113.93% |
| 2023 Q1 | -2958.00 USD | 21.25% |
| 2023 Q4 | 14.79 Thousand USD | 600.1% |
| 2023 Q3 | -2958.00 USD | 0.07% |
| 2023 Q2 | -2960.00 USD | -0.07% |
| 2023 FY | -11.83 Thousand USD | 21.12% |
| 2022 FY | -15 Thousand USD | -7.34% |
| 2022 Q1 | -3732.00 USD | 10.01% |
| 2022 Q2 | -3758.00 USD | -0.7% |
| 2022 Q4 | -3756.00 USD | 0.05% |
| 2022 Q3 | -3758.00 USD | 0.0% |
| 2021 Q1 | -3303.00 USD | 0.0% |
| 2021 Q3 | -3244.00 USD | 1.22% |
| 2021 Q2 | -3284.00 USD | 0.58% |
| 2021 Q4 | -4147.00 USD | -27.84% |
| 2021 FY | -13.97 Thousand USD | 51.86% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -29.03 Thousand USD | -40.55% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | -20.65 Thousand USD | -108.26% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | 250 Thousand USD | 0.0% |
| 2018 Q4 | - USD | -100.0% |
| 2018 Q1 | - USD | -100.0% |
| 2018 FY | 250 Thousand USD | 150.0% |
| 2017 FY | 100 Thousand USD | -50.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | 100 Thousand USD | 0.0% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q2 | 100 Thousand USD | 0.0% |
| 2016 Q4 | 100 Thousand USD | 0.0% |
| 2016 FY | 200 Thousand USD | 100.0% |
| 2016 Q1 | - USD | -100.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 100 Thousand USD | 0.0% |
| 2015 FY | 100 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | 100 Thousand USD | -66.67% |
| 2014 Q4 | 100 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q2 | 200 Thousand USD | 0.0% |
| 2013 Q4 | 100 Thousand USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 300 Thousand USD | 200.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | 100 Thousand USD | -60.0% |
| 2012 Q4 | 100 Thousand USD | 0.0% |
| 2012 Q1 | - USD | -100.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2011 FY | 250 Thousand USD | 150.0% |
| 2011 Q4 | 100 Thousand USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q2 | 150 Thousand USD | 0.0% |
| 2010 FY | 100 Thousand USD | -98.95% |
| 2010 Q1 | - USD | -100.0% |
| 2010 Q4 | 100 Thousand USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q4 | 100 Thousand USD | -98.56% |
| 2009 Q2 | 963.66 Thousand USD | -35.01% |
| 2009 FY | 9.5 Million USD | 51.61% |
| 2009 Q1 | 1.48 Million USD | 3.9% |
| 2009 Q3 | 6.95 Million USD | 621.61% |
| 2008 Q2 | 1.74 Million USD | -20.21% |
| 2008 FY | 6.26 Million USD | -15.99% |
| 2008 Q4 | 1.42 Million USD | 55.56% |
| 2008 Q3 | 917.47 Thousand USD | -47.28% |
| 2008 Q1 | 2.18 Million USD | 47.47% |
| 2007 Q4 | 1.47 Million USD | -27.73% |
| 2007 FY | 7.45 Million USD | 261.09% |
| 2007 Q1 | 1.56 Million USD | 27.2% |
| 2007 Q2 | 2.37 Million USD | 51.66% |
| 2007 Q3 | 2.04 Million USD | -13.67% |
| 2006 Q4 | 1.22 Million USD | 58.36% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q3 | 776 Thousand USD | 0.0% |
| 2006 Q1 | 60.83 Thousand USD | -64.81% |
| 2006 FY | 2.06 Million USD | 1020.47% |
| 2005 Q4 | 172.86 Thousand USD | 1628.6% |
| 2005 Q3 | 10 Thousand USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 Q1 | 1500.00 USD | -98.5% |
| 2005 FY | 184.36 Thousand USD | -56.94% |
| 2004 Q1 | 100 Thousand USD | 1326.94% |
| 2004 Q4 | 100 Thousand USD | 0.0% |
| 2004 Q2 | 228.16 Thousand USD | 128.16% |
| 2004 Q3 | - USD | -100.0% |
| 2004 FY | 428.16 Thousand USD | 355.49% |
| 2003 Q1 | 26.1 Thousand USD | -98.02% |
| 2003 FY | 94 Thousand USD | -92.94% |
| 2003 Q4 | 7008.00 USD | -78.89% |
| 2003 Q3 | 33.19 Thousand USD | 19.82% |
| 2003 Q2 | 27.69 Thousand USD | 6.11% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q2 | 75.2 Thousand USD | -93.34% |
| 2002 Q1 | 1.12 Million USD | -73.76% |
| 2002 Q4 | 1.31 Million USD | 0.0% |
| 2002 FY | 1.33 Million USD | -69.26% |
| 2001 Q3 | 7379.00 USD | 113.14% |
| 2001 Q1 | 316.74 Thousand USD | -89.61% |
| 2001 Q4 | 4.3 Million USD | 58236.66% |
| 2001 FY | 4.32 Million USD | 28.16% |
| 2001 Q2 | 3462.00 USD | -98.91% |
| 2000 Q3 | 121.92 Thousand USD | 3.56% |
| 2000 Q1 | 149.48 Thousand USD | 41.02% |
| 2000 FY | 3.37 Million USD | 457.39% |
| 2000 Q4 | 3.04 Million USD | 2401.43% |
| 2000 Q2 | 117.74 Thousand USD | -21.23% |
| 1999 Q2 | 200 Thousand USD | 100.0% |
| 1999 FY | 606 Thousand USD | -62.13% |
| 1999 Q4 | 106 Thousand USD | -47.0% |
| 1999 Q3 | 200 Thousand USD | 0.0% |
| 1999 Q1 | 100 Thousand USD | 111.11% |
| 1998 Q4 | -900 Thousand USD | -212.5% |
| 1998 FY | 1.6 Million USD | -79.75% |
| 1998 Q1 | 500 Thousand USD | 0.0% |
| 1998 Q2 | 700 Thousand USD | 40.0% |
| 1998 Q3 | 800 Thousand USD | 14.29% |
| 1997 Q1 | 1.6 Million USD | 420.0% |
| 1997 Q4 | 500 Thousand USD | -83.33% |
| 1997 Q3 | 3 Million USD | 200.0% |
| 1997 Q2 | 1 Million USD | -37.5% |
| 1997 FY | 7.9 Million USD | 507.69% |
| 1996 Q3 | 500 Thousand USD | -16.67% |
| 1996 Q2 | 600 Thousand USD | 50.0% |
| 1996 Q1 | 400 Thousand USD | 166.67% |
| 1996 FY | 1.3 Million USD | -23.53% |
| 1996 Q4 | -500 Thousand USD | -200.0% |
| 1995 Q3 | 800 Thousand USD | 0.0% |
| 1995 Q2 | 800 Thousand USD | 14.29% |
| 1995 Q1 | 700 Thousand USD | 16.67% |
| 1995 FY | 1.7 Million USD | -39.29% |
| 1995 Q4 | -600 Thousand USD | -175.0% |
| 1994 Q1 | 800 Thousand USD | 100.0% |
| 1994 Q3 | 700 Thousand USD | 0.0% |
| 1994 Q2 | 700 Thousand USD | -12.5% |
| 1994 FY | 2.8 Million USD | -39.13% |
| 1994 Q4 | 600 Thousand USD | -14.29% |
| 1993 Q3 | 1.3 Million USD | -13.33% |
| 1993 Q1 | 1.7 Million USD | 183.33% |
| 1993 Q2 | 1.5 Million USD | -11.76% |
| 1993 Q4 | 400 Thousand USD | -69.23% |
| 1993 FY | 4.6 Million USD | 84.0% |
| 1992 Q4 | 600 Thousand USD | 0.0% |
| 1992 Q3 | 600 Thousand USD | 0.0% |
| 1992 Q2 | 600 Thousand USD | 0.0% |
| 1992 Q1 | 600 Thousand USD | 20.0% |
| 1992 FY | 2.5 Million USD | -47.92% |
| 1991 FY | 4.8 Million USD | 1100.0% |
| 1991 Q4 | 500 Thousand USD | -68.75% |
| 1991 Q1 | 1.1 Million USD | 320.0% |
| 1991 Q2 | 1.6 Million USD | 45.45% |
| 1991 Q3 | 1.6 Million USD | 0.0% |
| 1990 Q4 | -500 Thousand USD | -266.67% |
| 1990 Q3 | 300 Thousand USD | -40.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q2 | 500 Thousand USD | 400.0% |
| 1990 FY | 400 Thousand USD | 123.53% |
| 1989 FY | -1.7 Million USD | -288.89% |
| 1989 Q3 | 200 Thousand USD | 100.0% |
| 1989 Q2 | 100 Thousand USD | 0.0% |
| 1989 Q1 | 100 Thousand USD | -66.67% |
| 1989 Q4 | - USD | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -385.24% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.101% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 96.296% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.01% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.954% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 75.476% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 90.475% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.079% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 481.528% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.121% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 118.006% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 65.344% |
| Mesoblast Limited | -35.16 Million USD | 99.966% |
| Marizyme, Inc. | 457.7 Thousand USD | 102.586% |
| Genus plc | 178.7 Million USD | 100.007% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.005% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 119.019% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 102.885% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -7.591% |
| ContraFect Corporation | -154 Thousand USD | 92.315% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 76.33% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 115.418% |
| IMV Inc. | -962.29 Thousand USD | 98.77% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 96.946% |
| MultiCell Technologies, Inc. | 49.32 USD | 24096.35% |
| ONE Bio Corp. | 20.12 Million USD | 100.059% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.029% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 124.202% |
| Q BioMed Inc. | -8988.00 USD | -31.676% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.042% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 23.269% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.027% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 98.963% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 116.907% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -138.994% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 108.423% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 87.863% |
| GB Sciences, Inc. | -624.00 USD | -1796.635% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 86.243% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -5589.904% |
| Enzolytics Inc. | 30.7 Thousand USD | 138.54% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 102.453% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.001% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 97.7% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 101.917% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.003% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -33.638% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 85.885% |
| Kadimastem Ltd | -630.13 Thousand USD | 98.122% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 101.198% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.123% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.077% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 106.703% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 106.703% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.872% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 59.19% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 102.63% |
| SYBLEU INC | 11.69 Thousand USD | 201.188% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.257% |
| Bioxytran, Inc. | -8285.00 USD | -42.849% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 96.827% |
| Neutra Corp. | 14.33 Thousand USD | 182.56% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 85.567% |
| PureTech Health plc | -1.6 Million USD | 99.262% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 98.818% |
| IXICO plc | 3.27 Million USD | 100.362% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 98.295% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.339% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 165.75% |